Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 175

The DOI matches its Crossref record.

A Multiinstitutional Phase 2 Trial of Pazopanib Monotherapy in Advanced Anaplastic Thyroid Cancer

Open access
Bible, Keith C., Suman, Vera J., Menefee, Michael E., Smallridge, Robert C., Molina, Julian R., Maples, William J., Karlin, Nina J., Traynor, Anne M., Kumar, Priya, Goh, Boon Cher, Lim, Wan-Teck, Bossou, Ayoko R., Isham, Crescent R., Webster, Kevin P., Kukla, Andrea K., Bieber, Carolyn, Burton, Jill K., Harris, Pamela, Erlichman, Charles, the Mayo Phase 2 Consortium and Mayo Clinic Endocrine Malignances Disease Oriented Group · 2012 · The Journal of Clinical Endocrinology & Metabolism

Abstract

CONTEXT/OBJECTIVES: Pazopanib, an inhibitor of kinases including vascular endothelial growth factor receptor, demonstrated impressive activity in progressive metastatic differentiated thyroid cancer, prompting its evaluation in anaplastic thyroid cancer (ATC). DESIGN/SETTING/PATIENTS/INTERVENTIONS/OUTCOME MEASURES: Preclinical studies, followed by a multicenter single arm phase 2 trial of continuously administered 800 mg pazopanib daily by mouth (designed to provide 90% chance of detecting a response rate of >20% at the 0.10 significance level when the true response rate is >5%), were undertaken. The primary trial end point was Response Evaluation Criteria in Solid Tumors (RECIST) response. RESULTS: Pazopanib displayed activity in the KTC2 ATC xenograft model, prompting clinical evaluation. Sixteen trial patients were enrolled; 15 were treated: 66.7% were female, median age was 66 yr (range 45-77 yr), and 11 of 15 had progressed through prior systemic therapy. Enrollment was halted, triggered by a stopping rule requiring more than one confirmed RECIST response among the first 14 of 33 potential patients. Four patients required one to two dose reductions; severe toxicities (National Cancer Institute Common Toxicity Criteria-Adverse Events version 3.0 grades >3) were hypertension (13%) and pharyngolaryngeal pain (13%). Treatment was discontinued because of the following: disease progression (12 patients), death due to a possibly treatment-related tumor hemorrhage (one patient), and intolerability (radiation recall tracheitis and uncontrolled hypertension, one patient each). Although transient disease regression was observed in several patients, there were no confirmed RECIST responses. Median time to progression was 62 d; median survival time was 111 d. Two patients are alive with disease 9.9 and 35 months after the registration; 13 died of disease. CONCLUSIONS: Despite preclinical in vivo activity in ATC, pazopanib has minimal single-agent clinical activity in advanced ATC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2012-1520

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 175

Metadata

Authors
Bible, K. C., Suman, V. J., Menefee, M. E., Smallridge, R. C., Molina, J. R., Maples, W. J., Karlin, N. J., Traynor, A. M., Kumar, P., Goh, B. C., Lim, W.-T., Bossou, A. R., Isham, C. R., Webster, K. P., Kukla, A. K., Bieber, C., Burton, J. K., Harris, P., Erlichman, C., & the Mayo Phase 2 Consortium and Mayo Clinic Endocrine Malignances Disease Oriented Group
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2012-09-01
Volume
97
Issue
9
Pages
3179-3184
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W1989932167
Cited by
175
References
0
FWCI
8.97
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Multiinstitutional Phase 2 Trial of Pazopanib Monotherapy in Advanced Anaplastic Thyroid Cancer. https://app.cochat.ai/papers/10.1210/jc.2012-1520
The paper
Bible, K. C., Suman, V. J., Menefee, M. E., Smallridge, R. C., Molina, J. R., Maples, W. J., Karlin, N. J., Traynor, A. M., Kumar, P., Goh, B. C., Lim, W.-T., Bossou, A. R., Isham, C. R., Webster, K. P., Kukla, A. K., Bieber, C., Burton, J. K., Harris, P., Erlichman, C., & the Mayo Phase 2 Consortium and Mayo Clinic Endocrine Malignances Disease Oriented Group. (2012). A Multiinstitutional Phase 2 Trial of Pazopanib Monotherapy in Advanced Anaplastic Thyroid Cancer. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2012-1520

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.